15 February 2021 - The UK’s NICE has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.

Lilly had been seeking a recommendation within Verzenios’ marketing authorisation, for treating hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer in adults who have had endocrine therapy.

Read Pharma Times article